infections
Industry
Sponsored by
A new scientific publication on the beneficial effect of probiotics on cold symptoms relief, immune response enhancement, and quality of life in healthy adults during winter seasons.
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
Nutrient competition is the main mechanism of C. difficile inhibition, hinting at the potential for targeted therapies with probiotics instead of traditional FMT.
By addressing biases and increasing diversity in microbiota studies, researchers can develop more accurate and inclusive health strategies for women of different backgrounds.
The approval is major step forward in the fight against recurrent C. diff infection.
Certain features of the vaginal microbiota, including specific bacterial communities, could indicate an increased Chlamydia infection risk.
Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.
Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
